Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech"), a subsidiary of Sichuan Kelun Pharmaceutical Co.,...
CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET
ATLANTA, Sept. 27, 2022 /PRNewswire/ -- CP Kelco, a global leader of nature-based ingredient solutions that is owned by J.M. Huber Corporation, and ExoPolymer, Inc., a biotechnology startup company focused on developing new-to-the-world, polysaccharide-based biopolymers, are excited to announce a partnership to develop and commercialize a portfolio of new functional ingredients for the personal care industry and beyond. ...
Neurophth announces first patient dosed in Phase III clinical trial for the gene therapy treatment of LHON
WUHAN, China and SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a Phase I/II/III, multi-center, two-parts study aimed at evaluating the safety, tolerability,...
Metabolon Expands Data Access Strategy to Include Health for Life in Singapore (HELIOS) Study
Metabolon to collaborate with NTU Singapore's medical school to identify biomarkers for the prevention, diagnosis, and treatment of disease. MORRISVILLE, N.C., Sept. 27, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a...
TargEDys and Inoliva announce they have entered a distribution partnership to bring Satylia® to Turkey
LONGJUMEAU, France, Sept. 27, 2022 /PRNewswire/ -- TargEDys and Inoliva, an affiliate of Abdi Ibrahim, have signed an exclusive marketing and distribution agreement to bring Satylia, a food supplement based on the next-generation probiotic Hafnia alvei HA4597, to the Turkish market. Satylia, also called EnteroSatys in other markets, is a precision probiotic with...
Amaris B. Clinic awarded the “Body Sculpting Medical Centre of the Year in Asia Pacific” for four years in a row by GlobalHealth Asia-Pacific
According to GlobalHealth Asia-Pacific, "the distinguished awards honour clinics and medical centres, who have been playing an increasingly critical role within the patient journey and in setting the highest standards in the delivery of care." SINGAPORE, Sept. 27, 2022 /PRNewswire/ -- Amaris B. Clinic was conferred the "Body Sculpting Medical Centre of the Year in Asia Pacific 2022"...
How Healthcare Organizations Can Enhance a Holistic Patient and Member View by Improving Insights from Data
A future-proof enterprise content management and enterprise imaging strategy across healthcare organizations enables individualized experiences, cost-saving efficiencies, and productivity gains SAN ANTONIO, Texas, Sept. 27, 2022 /PRNewswire/ -- The current dynamic transformation that healthcare organizations are going through demands structuring and aligning IT with current and future needs. As healthcare providers become more data driven, organizational leaders need to take...
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
JIAXING,China and BURLINGAME,Calif., Sept. 27, 2022 /PRNewswire/ -- Angel Pharmaceuticals Ltd. ("Angel Pharma"), a clinical-stage biopharmaceutical company, today announced that the IND application for mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation (CDE) to initiate a Phase 1/1b clinical trial in China. Angel Pharma owns mupadolimab's rights in Greater China. Mupadolimab is a humanized monoclonal...
Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics
The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA delivery technology and expertise in developing RNAi therapeutics SAN FRANCISCO, Calif. and HANGZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease，and SynerK, a leading RNAi therapeutics discovery and...
Luye Pharma Enters Local Seroquel® Distribution and Marketing Partnership with ICI Pakistan Limited
"We Care About Mental Health" awareness set to increase across APAC Luye Pharma has granted ICI Pakistan Limited exclusive distribution and marketing rights for Seroquel® in Pakistan. As part of the "We Care About Mental Health" initiative, the two companies have pledged to make joint efforts to raise awareness regarding mental health issues. SHANGHAI, Sept. 27, 2022...
